Table 1. Patient exposure to PEG-J across the LCIG phase 3 program.
| Duration interval (days) | PEG-J exposure (n=395), patients, n (%)a |
|---|---|
| 1–14 | 9 (2.3) |
| 15–29 | 4 (1.0) |
| 30–59 | 7 (1.8) |
| 60–89 | 10 (2.5) |
| 90–179 | 14 (3.5) |
| 180–364 | 44 (11) |
| 365–729 | 194 (49) |
| ≥730 | 113 (29) |
| At least 6 months (≥180 days) | 351 (89) |
| At least 12 months (≥364 days) | 307 (78) |
| At least 18 months (≥540 days) | 180 (46) |
| Mean (s.d.) | 546 (299) |
| Median (min/max) | 480 (1/1,276) |
LCIG, levodopa-carbidopa intestinal gel; min/max, minimum/maximum; PEG-J, percutaneous endoscopic gastrojejunostomy.
a
Exposure is difference between start date (PEG-J placement) and end date (the last dose of study drug or PEG-J removal, whichever is later); 208 patients were available at the time of data cutoff.